@misc{10481/62744,
year = {2020},
month = {5},
url = {http://hdl.handle.net/10481/62744},
abstract = {Despite being largely preventable through early vaccination and screening strategies,
cervical cancer is the most common type of gynecological malignancy worldwide and constitutes one
of the leading causes of cancer deaths in women. Patients with advanced or recurrent disease have a
very poor prognosis; hence, novel therapeutic modalities to improve clinical outcomes in cervical
malignancy are needed. In this regard, targeted gene delivery therapy is presented as a promising
approach, which leads to the development of multiple strategies focused on different aspects. These
range from altered gene restoration, immune system potentiation, and oncolytic virotherapy to the
use of nanotechnology and the design of improved and enhanced gene delivery systems, among
others. In the present manuscript, we review the current progress made in targeted gene delivery
therapy for cervical cancer, the advantages and drawbacks and their clinical application. At present,
multiple targeted gene delivery systems have been reported with encouraging preclinical results.
However, the translation to humans has not yet shown a significant clinical benefit due principally to
the lack of efficient vectors. Real efforts are being made to develop new gene delivery systems, to
improve tumor targeting and to minimize toxicity in normal tissues.},
organization = {This research was supported by the Fundación Mutua Madrileña (project FMM-AP16683-2017) and
Consejería de Salud Junta de Andalucía (PI-0089-2017).},
publisher = {MDPI},
keywords = {Cervical cancer},
keywords = {Targeted gene therapy},
keywords = {Delivery systems},
keywords = {Immunopotentiation},
keywords = {Cervical cancer stem cells},
title = {Targeted Gene Delivery Therapies for Cervical Cancer},
doi = {10.3390/cancers12051301},
author = {Áyen, Ángela and Jiménez Martínez, Yaiza and Boulaiz Tassi, Houria},
}